These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18056431)

  • 41. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
    Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The p53/miR-34 axis in development and disease.
    Rokavec M; Li H; Jiang L; Hermeking H
    J Mol Cell Biol; 2014 Jun; 6(3):214-30. PubMed ID: 24815299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.
    Boominathan L
    Cancer Metastasis Rev; 2010 Dec; 29(4):613-39. PubMed ID: 20922462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met.
    Wang LG; Ni Y; Su BH; Mu XR; Shen HC; Du JJ
    Int J Oncol; 2013 Mar; 42(3):957-62. PubMed ID: 23314612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The p53/microRNA network in cancer: experimental and bioinformatics approaches.
    Hünten S; Siemens H; Kaller M; Hermeking H
    Adv Exp Med Biol; 2013; 774():77-101. PubMed ID: 23377969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
    Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
    PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.
    Braun CJ; Zhang X; Savelyeva I; Wolff S; Moll UM; Schepeler T; Ørntoft TF; Andersen CL; Dobbelstein M
    Cancer Res; 2008 Dec; 68(24):10094-104. PubMed ID: 19074875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p53 shapes genome-wide and cell type-specific changes in microRNA expression during the human DNA damage response.
    Hattori H; Janky R; Nietfeld W; Aerts S; Madan Babu M; Venkitaraman AR
    Cell Cycle; 2014; 13(16):2572-86. PubMed ID: 25486198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
    Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-transcriptional regulation of the tumor suppressor p53 by a novel miR-27a, with implications during hypoxia and tumorigenesis.
    Maqbool R; Lone SN; Ul Hussain M
    Biochem J; 2016 Oct; 473(20):3597-3610. PubMed ID: 27531966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PDL1 Regulation by p53 via miR-34.
    Cortez MA; Ivan C; Valdecanas D; Wang X; Peltier HJ; Ye Y; Araujo L; Carbone DP; Shilo K; Giri DK; Kelnar K; Martin D; Komaki R; Gomez DR; Krishnan S; Calin GA; Bader AG; Welsh JW
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26577528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
    Do MT; Kim HG; Choi JH; Jeong HG
    Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The P53/microRNA network: A potential tumor suppressor with a role in anticancer therapy.
    Sargolzaei J; Etemadi T; Alyasin A
    Pharmacol Res; 2020 Oct; 160():105179. PubMed ID: 32890739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
    Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.
    Raver-Shapira N; Marciano E; Meiri E; Spector Y; Rosenfeld N; Moskovits N; Bentwich Z; Oren M
    Mol Cell; 2007 Jun; 26(5):731-43. PubMed ID: 17540598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.
    Lodygin D; Tarasov V; Epanchintsev A; Berking C; Knyazeva T; Körner H; Knyazev P; Diebold J; Hermeking H
    Cell Cycle; 2008 Aug; 7(16):2591-600. PubMed ID: 18719384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
    Heinemann A; Zhao F; Pechlivanis S; Eberle J; Steinle A; Diederichs S; Schadendorf D; Paschen A
    Cancer Res; 2012 Jan; 72(2):460-71. PubMed ID: 22102694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway.
    Wongjampa W; Ekalaksananan T; Chopjitt P; Chuerduangphui J; Kleebkaow P; Patarapadungkit N; Pientong C
    PLoS One; 2018; 13(10):e0206644. PubMed ID: 30379969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.
    Tazawa H; Tsuchiya N; Izumiya M; Nakagama H
    Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15472-7. PubMed ID: 17875987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNAs in the p53 network: micromanagement of tumour suppression.
    Hermeking H
    Nat Rev Cancer; 2012 Sep; 12(9):613-26. PubMed ID: 22898542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.